Table of Contents Author Guidelines Submit a Manuscript
Disease Markers
Volume 2015, Article ID 591454, 7 pages
http://dx.doi.org/10.1155/2015/591454
Research Article

The Apolipoprotein B/Apolipoprotein A-I Ratio as a Potential Marker of Plasma Atherogenicity

1Institute of Physiology, Komi Science Center, Ural Branch of Russian Academy of Sciences, Pervomaiskaya Avenue 50, Syktyvkar 167982, Russia
2Faculty of Health Sciences, The Arctic University of Norway, 9037 Tromsø, Norway

Received 25 November 2014; Revised 18 February 2015; Accepted 25 February 2015

Academic Editor: Benoit Dugue

Copyright © 2015 Anastasiya M. Kaneva et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. Y. Sherer and Y. Shoenfeld, “Mechanisms of disease: atherosclerosis in autoimmune diseases,” Nature Clinical Practice Rheumatology, vol. 2, no. 2, pp. 99–106, 2006. View at Publisher · View at Google Scholar · View at Scopus
  2. C. Schmidt, B. Fagerberg, J. Wikstrand, and J. Hulthe, “ApoB/apoA-I ratio is related to femoral artery plaques and is predictive for future cardiovascular events in healthy men,” Atherosclerosis, vol. 189, no. 1, pp. 178–185, 2006. View at Publisher · View at Google Scholar · View at Scopus
  3. S. Yusuf, S. Hawken, S. Ounpuu et al., “Effect of potentially modifiable risk factors associated with myocardial infarction in 52 countries (the INTERHEART study): case-control study,” The Lancet, vol. 364, no. 9438, pp. 937–952, 2004. View at Google Scholar
  4. A. D. Sniderman, I. Junger, I. Holme, A. Aastveit, and G. Walldius, “Errors that result from using the TC/HDL C ratio rather than the apoB/apoA-I ratio to identify the lipoprotein-related risk of vascular disease,” Journal of Internal Medicine, vol. 259, no. 5, pp. 455–461, 2006. View at Publisher · View at Google Scholar · View at Scopus
  5. G. Walldus, I. Jungner, A. H. Aastveit, I. Holme, C. D. Furberg, and A. D. Sniderman, “The apoB/apoA-I ratio is better than the cholesterol ratios to estimate the balance between plasma proatherogenic and antiatherogenic lipoproteins and to predict coronary risk,” Clinical Chemistry and Laboratory Medicine, vol. 42, no. 12, pp. 1355–1363, 2004. View at Publisher · View at Google Scholar · View at Scopus
  6. L. Johansson and C. Schmidt, “Increased apoB/apoA-I ratio is predictive of peripheral arterial disease in initially healthy 58-year-old men during 8.9 years of follow-up,” Angiology, vol. 60, no. 5, pp. 539–545, 2009. View at Publisher · View at Google Scholar · View at Scopus
  7. G. S. Ginsburg, C. Safran, and R. C. Pasternak, “Frequency of low serum high-density lipoprotein cholesterol levels in hospitalized patients with ‘desirable’ total cholesterol levels,” The American Journal of Cardiology, vol. 68, no. 2, pp. 187–192, 1991. View at Publisher · View at Google Scholar · View at Scopus
  8. J. Genest Jr., J. R. McNamara, J. M. Ordovas et al., “Lipoprotein cholesterol, apolipoprotein A-I and B and lipoprotein (a) abnormalities in men with premature coronary artery disease,” Journal of the American College of Cardiology, vol. 19, no. 4, pp. 792–802, 1992. View at Publisher · View at Google Scholar · View at Scopus
  9. H. R. Superko, “Beyond LDL cholesterol reduction,” Circulation, vol. 94, no. 10, pp. 2351–2354, 1996. View at Publisher · View at Google Scholar · View at Scopus
  10. J. E. R. van Lennep, H. T. Westerveld, H. W. O. R. van Lennep, A. H. Zwinderman, D. W. Erkelens, and E. E. van der Wall, “Apolipoprotein concentrations during treatment and recurrent coronary artery disease events,” Arteriosclerosis, Thrombosis, and Vascular Biology, vol. 20, no. 11, pp. 2408–2413, 2000. View at Publisher · View at Google Scholar · View at Scopus
  11. S. R. Srinivasan and G. S. Berenson, “Serum apolipoproteins A-I and B as markers of coronary artery disease risk in early life: the Bogalusa Heart Study,” Clinical Chemistry, vol. 41, no. 1, pp. 159–164, 1995. View at Google Scholar · View at Scopus
  12. A. D. Sniderman, T. Pedersen, and J. Kjekshus, “Putting low-density lipoproteins at center stage in atherogenesis,” The American Journal of Cardiology, vol. 79, no. 1, pp. 64–67, 1997. View at Publisher · View at Google Scholar · View at Scopus
  13. J. Elovson, J. E. Chatterton, G. T. Bell et al., “Plasma very low density lipoproteins contain a single molecule of apolipoprotein B,” Journal of Lipid Research, vol. 29, no. 11, pp. 1461–1473, 1988. View at Google Scholar · View at Scopus
  14. G. Walldius and I. Jungner, “Apolipoprotein B and apolipoprotein A-I: risk indicators of coronary heart disease and targets for lipid-modifying therapy,” Journal of Internal Medicine, vol. 255, no. 2, pp. 188–205, 2004. View at Publisher · View at Google Scholar · View at Scopus
  15. G. Walldius, “The apoB/apoA-I ratio is a strong predictor of cardiovascular risk,” in Lipoproteins in Health and Diseases, S. Frank and G. Kostner, Eds., pp. 95–148, InTech, Rijeka, Croatia, 2012. View at Google Scholar
  16. A. Thompson and J. Danesh, “Associations between apolipoprotein B, apolipoprotein AI, the apolipoprotein B/AI ratio and coronary heart disease: a literature-based meta-analysis of prospective studies,” Journal of Internal Medicine, vol. 259, no. 5, pp. 481–492, 2006. View at Publisher · View at Google Scholar · View at Scopus
  17. M. S. Graziani, L. Zanolla, G. Righetti, C. Marchetti, P. Mocarelli, and S. M. Marcovina, “Plasma apolipoproteins A-I and B in survivors of myocardial infarction and in a control group,” Clinical Chemistry, vol. 44, no. 1, pp. 134–140, 1998. View at Google Scholar · View at Scopus
  18. A. Sniderman, S. Shapiro, D. Marpole, B. Skinner, B. Teng, and P. O. Kwiterovich Jr., “Association of coronary atherosclerosis with hyperapobetalipoproteinemia [increased protein but normal cholesterol levels in human plasma low density (β) lipoproteins],” Proceedings of the National Academy of Sciences of the United States of America, vol. 77, no. 1, pp. 604–608, 1980. View at Publisher · View at Google Scholar · View at Scopus
  19. J. R. Crouse, J. S. Parks, H. M. Schey, and F. R. Kahl, “Studies of low density lipoprotein molecular weight in human beings with coronary artery disease,” Journal of Lipid Research, vol. 26, no. 5, pp. 566–574, 1985. View at Google Scholar · View at Scopus
  20. M. A. Austin, J. L. Breslow, C. H. Hennekens, J. E. Buring, W. C. Willett, and R. M. Krauss, “Low-density lipoprotein subclass patterns and risk of myocardial infarction,” The Journal of the American Medical Association, vol. 260, no. 13, pp. 1917–1921, 1988. View at Publisher · View at Google Scholar · View at Scopus
  21. J. H. Contois, J. R. Mcnamara, C. J. Lammi-Keefe, P. W. F. Wilson, T. Massov, and E. J. Schaefer, “Reference intervals for plasma apolipoprotein B determined with a standardized commercial immunoturbidimetric assay: results from the Framingham Offspring Study,” Clinical Chemistry, vol. 42, no. 4, pp. 515–523, 1996. View at Google Scholar · View at Scopus
  22. J. H. Contois, J. R. Mcnamara, C. J. Lammi-Keefe, P. W. F. Wilson, T. Massov, and E. J. Schaefer, “Reference intervals for plasma apolipoprotein A-I determined with a standardized commercial immunoturbidimetric assay: results from the Framingham Offspring Study,” Clinical Chemistry, vol. 42, no. 4, pp. 507–514, 1996. View at Google Scholar · View at Scopus
  23. G. Walldius, I. Jungner, I. Holme, A. H. Aastveit, W. Kolar, and E. Steiner, “High apolipoprotein B, low apolipoprotein A-I, and improvement in the prediction of fatal myocardial infarction (AMORIS study): a prospective study,” The Lancet, vol. 358, no. 9298, pp. 2026–2033, 2001. View at Publisher · View at Google Scholar · View at Scopus
  24. P. J. Talmud, E. Hawe, G. J. Miller, and S. E. Humphries, “Nonfasting apolipoprotein B and triglyceride levels as a useful predictor of coronary heart disease risk in middle-aged UK men,” Arteriosclerosis, Thrombosis, and Vascular Biology, vol. 22, no. 11, pp. 1918–1923, 2002. View at Publisher · View at Google Scholar · View at Scopus
  25. K. Dunder, L. Lind, B. Zethelius, L. Berglund, and H. Lithell, “Evaluation of a scoring scheme, including proinsulin and the apolipoprotein B/apolipoprotein A1 ratio, for the risk of acute coronary events in middle-aged men: Uppsala Longitudinal Study of Adult Men (ULSAM),” The American Heart Journal, vol. 148, no. 4, pp. 596–601, 2004. View at Publisher · View at Google Scholar · View at Scopus
  26. L. Lind, B. Vessby, and J. Sundström, “The apolipoprotein B/AI ratio and the metabolic syndrome independently predict risk for myocardial infarction in middle-aged men,” Arteriosclerosis, Thrombosis, and Vascular Biology, vol. 26, no. 2, pp. 406–410, 2006. View at Publisher · View at Google Scholar · View at Scopus
  27. W. A. van der Steeg, S. M. Boekholdt, E. A. Stein et al., “Role of the apolipoprotein B-apolipoprotein A-I ratio in cardiovascular risk assessment: a case-control analysis in EPIC-Norfolk,” Annals of Internal Medicine, vol. 146, no. 9, pp. 640–648, 2007. View at Publisher · View at Google Scholar · View at Scopus
  28. M. J. McQueen, S. Hawken, X. Wang et al., “Lipids, lipoproteins, and apolipoproteins as risk markers of myocardial infarction in 52 countries (the INTERHEARTstudy): a case–control study,” The Lancet, vol. 372, no. 9634, pp. 224–233, 2008. View at Publisher · View at Google Scholar · View at Scopus
  29. G. P. C. Schianca, R. Pedrazzoli, S. Onolfo et al., “ApoB/apoA-I ratio is better than LDL-C in detecting cardiovascular risk,” Nutrition, Metabolism and Cardiovascular Diseases, vol. 21, no. 6, pp. 406–411, 2011. View at Publisher · View at Google Scholar · View at Scopus
  30. G. Walldius and I. Jungner, “The apoB/apoA-I ratio: a strong, new risk factor for cardiovascular disease and a target for lipid-lowering therapy—a review of the evidence,” Journal of Internal Medicine, vol. 259, no. 5, pp. 493–519, 2006. View at Publisher · View at Google Scholar · View at Scopus
  31. W. T. Friedewald, R. I. Levy, and D. S. Fredrickson, “Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge,” Clinical Chemistry, vol. 18, no. 6, pp. 499–502, 1972. View at Google Scholar · View at Scopus
  32. M. Dobiášová and J. Frohlich, “The plasma parameter log (TG/HDL-C) as an atherogenic index: correlation with lipoprotein particle size and esterification rate inapoB-lipoprotein-depleted plasma (FERHDL),” Clinical Biochemistry, vol. 34, no. 7, pp. 583–588, 2001. View at Publisher · View at Google Scholar · View at Scopus
  33. W. B. Kannel, W. P. Castelli, T. Gordon, and P. M. McNamara, “Serum cholesterol, lipoproteins, and the risk of coronary heart disease. The Framingham Study,” Annals of Internal Medicine, vol. 74, no. 1, pp. 1–12, 1971. View at Publisher · View at Google Scholar · View at Scopus
  34. S. M. Grundy, D. Bilheimer, A. Chait et al., “Summary of the second report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel II),” Journal of the American Medical Association, vol. 269, no. 23, pp. 3015–3023, 1993. View at Publisher · View at Google Scholar · View at Scopus
  35. J. Millán, X. Pintó, A. Muñoz et al., “Lipoprotein ratios: physiological significance and clinical usefulness in cardiovascular prevention,” Vascular Health and Risk Management, vol. 5, pp. 757–765, 2009. View at Google Scholar · View at Scopus
  36. H. T. Westerveld, J. E. van Roeters Lennep, H. W. O. van Roeters Lennep et al., “Apolipoprotein B and coronary artery disease in women: a cross-sectional study in women undergoing their first coronary angiography,” Arteriosclerosis, Thrombosis, and Vascular Biology, vol. 18, no. 7, pp. 1101–1107, 1998. View at Publisher · View at Google Scholar · View at Scopus
  37. M. Haidari, M. Moghadam, M. Chinicar, A. Ahmadieh, and M. Doosti, “Apolipoprotein B as the best predictor of coronary artery disease in Iranian normolipidemic patients,” Clinical Biochemistry, vol. 34, no. 2, pp. 149–155, 2001. View at Publisher · View at Google Scholar · View at Scopus
  38. C. Snehalatha, A. Ramachandran, S. Sivasankari et al., “Is increased apolipoprotein B-A major factor enhancing the risk of coronary artery disease in type 2 diabetes?” Journal of Association of Physicians of India, vol. 50, no. 8, pp. 1036–1038, 2002. View at Google Scholar · View at Scopus
  39. H.-K. Kim, S.-A. Chang, E.-K. Choi et al., “Association between plasma lipids, and apolipoproteins and coronary artery disease: a cross-sectional study in a low-risk Korean population,” International Journal of Cardiology, vol. 101, no. 3, pp. 435–440, 2005. View at Publisher · View at Google Scholar · View at Scopus
  40. A. M. Wägner, O. Jorba, M. Rigla, E. Alonso, J. Ordóñez-Llanos, and A. Pérez, “LDL-cholesterol/apolipoprotein B ratio is a good predictor of LDL phenotype B in type 2 diabetes,” Acta Diabetologica, vol. 39, no. 4, pp. 215–220, 2002. View at Publisher · View at Google Scholar · View at Scopus
  41. S. Marcovina and C. J. Packard, “Measurement and meaning of apolipoprotein AI and apolipoprotein B plasma levels,” Journal of Internal Medicine, vol. 259, no. 5, pp. 437–446, 2006. View at Publisher · View at Google Scholar · View at Scopus
  42. N. F. Galeano, M. Al-Haideri, F. Keyserman, S. C. Rumsey, and R. J. Deckelbaum, “Small dense low density lipoprotein has increased affinity for LDL receptor-independent cell surface binding sites: a potential mechanism for increased atherogenicity,” Journal of Lipid Research, vol. 39, no. 6, pp. 1263–1273, 1998. View at Google Scholar · View at Scopus
  43. R. W. Mahley, K. H. Weisgraber, and Y. Huang, “Apolipoprotein E: structure determines function, from atherosclerosis to Alzheimer's disease to AIDS,” Journal of Lipid Research, vol. 50, supplement, pp. S183–S188, 2009. View at Publisher · View at Google Scholar · View at Scopus
  44. A. M. Kaneva, E. R. Bojko, N. N. Potolitsyna, and J. O. Odland, “Plasma levels of apolipoprotein-E in residents of the European North of Russia,” Lipids in Health and Disease, vol. 12, no. 1, article 43, 2013. View at Publisher · View at Google Scholar · View at Scopus
  45. E. R. Boǐko, A. M. Kaneva, and N. N. Potolitsyna, “Functional importance of apolipoprotein-E in lipid metabolism in inhabitants of the European North,” Fiziologiya Cheloveka, vol. 36, no. 2, pp. 138–144, 2010. View at Google Scholar · View at Scopus